Objective: Identification and examination of all patients with multifocal motor neuropathy (MMN) in the Netherlands to document the clinical spectrum and response to IV immunoglobulin (IVIg) and to determine correlates of outcome.
Several small and medium-sized cohort studies and a few elaborate reviews have highlighted clinical features of MMN, [11] [12] [13] [14] [15] [16] but the relative rarity has precluded detailed studies of the phenotype and correlates of outcome in larger numbers of patients. We, therefore, tried to identify and reexamine all patients with MMN in the Netherlands (population 16.4 million) to document the variety of clinical phenotypes and response to IVIg treatment. The relatively large number of patients enabled us to investigate the correlates of outcome in a multivariate analysis.
METHODS Patients. The study had a cross-sectional descriptive study design and was conducted in the Netherlands from January until December 2007. To identify patients with MMN, all Dutch neurologists (ϳ900) were asked by letter to enroll patients with MMN, a national neuromuscular database (CRAMP) 17 was screened, and patients were informed by the Dutch Neuromuscular Patient Association.
Inclusion criteria were a diagnosis of definite, probable, or possible MMN, according to previously published criteria. 18 All patients had slow or stepwise progressive limb weakness, no objective sensory abnormalities except for vibration sense at onset, no bulbar signs, no upper motor neuron signs, and no other cause of neuropathy or myopathy. Patients with definite MMN had at least 1 definite motor CB, patients with probable MMN had at least 1 probable motor CB, and patients with possible MMN had conduction slowing compatible with demyelination in addition to elevated serum immunoglobulin M (IgM) anti-GM1 antibody titers or abnormal brachial plexus MRI. 19 Patients had normal sensory nerve conduction in segments with motor CB and normal distal sensory nerve action potential amplitudes at the first nerve conduction study. IVIg responsiveness was not part of the diagnostic criteria.
Patients were requested to fill out a questionnaire and to attend the University Medical Center (UMC) Utrecht for a full neurologic reexamination.
Standard protocol approvals, registrations, and patient consents. The study protocol was approved by the institutional committee of the UMC Utrecht. All patients gave written informed consent prior to the study.
Questionnaires and physical examination. All patients completed a questionnaire designed to clarify their medical history, site of onset, initial diagnosis, and treatment. Muscle strength was assessed bilaterally using a modified 10-grade scale of the Medical Research Council (MRC) ranging from 0 (no movement, no contraction) to 5 (normal). Eleven muscle groups of arms and 7 muscle groups of legs were tested. Weakness was defined as an MRC score lower than 5. The MRC sumscore was calculated (maximum 180). Tendon reflexes of biceps, triceps, knee, and ankle were scored as absent, normal, or brisk. Sensory function was assessed bilaterally in arms and legs using a Rydel-Seiffer tuning fork for vibration sense. 20 Vibration sense was graded from normal (grade 0) to disturbed at the acromioclavicular joint or anterior superior iliac spine (grade 4). 21 Laboratory studies. Serum samples were taken from all patients and tested for IgM anti-GM1 antibodies using standardized ELISA. 22 Nerve conduction studies. Nerve conduction studies were performed and studied by 1 investigator (H.F.). Prior to investigation, the extremities were warmed in water at 37°C for 30 minutes. Motor nerve conduction was investigated up to Erb's point in the median, ulnar, radial, and musculocutaneous nerves, and up to the popliteal fossa in the peroneal and tibial nerves. 23 To assess CB, the CMAP on stimulation of the distal part of the segment with CB had to be at least 1 mV, and 0.5 mV to assess demyelinative slowing. Conduction abnormalities were defined as definite CB (compound muscle action potential [CMAP] area reduction of at least 50%); probable CB (CMAP area reduction of 30%-50% in an arm nerve 24 ); demyelinative slowing (motor conduction velocity [MCV] Ͻ75% of the lower limit of normal, distal motor latency [DML] or shortest F-wave latency 130% of the upper limit of normal).
Presence of a decreased distal CMAP (distal CMAP amplitude below the lower limit of normal 25 ) was scored for the median, ulnar, radial, musculocutaneous, peroneal, and tibial nerves on both sides, and was considered to reflect axon loss. 25, 26 Functional impairment and fatigue. Functional impairment was assessed using the Overall Disability Sum Score (ODSS) ranging from 0 (normal) to 5 for the arms and to 7 for the legs. 27 Fatigue was scored using the Fatigue Severity Scale (FSS). 28 The patient was asked to read 9 statements and circle a number from 1 (not very appropriate) to 7 (agreement). Final scores were calculated by determining the mean of responses. Severe fatigue was defined as a score exceeding the FSS 95th percentile (5) in healthy controls.
Statistical analysis and determinants of outcome.
Differences were tested with the Mann-Whitney U test and the 2 test. To identify determinants of outcome, logistic regression analysis was performed. More severe weakness was defined as lower MRC sumscore than the median, and more severe disability as a lower than median ODSS score for arms and legs. Determinants for weakness and disability were first analyzed with univariate analysis. Next, multivariate analysis was performed to determine the independent contribution of each potential determinant. The determinants gender (male/female), symptom onset in a leg (yes/no), IgM anti-GM1 antibodies (positive/ negative), and severe fatigue (FSS 5 or more/FSS less than 5) were analyzed as dichotomous variables; age at symptom onset, years untreated (disease duration without IVIg), duration of IVIg treatment, and axon loss (number of nerves with decreased distal CMAP) were analyzed as continuous variables.
Classification of evidence.
This study provides Class IV evidence that IVIg improves muscle strength (defined as an increase of Ն1 MRC grade in at least 2 muscle groups without decrease in other muscle groups) in patients with MMN and disability.
RESULTS

Patients.
Ninety-seven patients with MMN were identified. Eighty-eight patients (91%) agreed to participate. Fifty-five patients were recruited from the UMC Utrecht; 29 patients were en-rolled by notified neurologists, and screening the neuromuscular database resulted in identification of an additional 4 patients.
Patient characteristics are shown in table 1. The male to female ratio was 2.7:1. Age at onset was younger in men (38 years) than in women (45 years) ( p ϭ 0.05).
Onset of muscle weakness was most frequently in the distal arm (61%) or distal leg (34%). Muscle weakness occasionally started in the upper arm (5%), but never in the upper leg. Symptom onset was more often in the dominant hand ( p ϭ 0.04).
The initial diagnosis was different from MMN in the majority of patients. The median delay from first symptoms to the diagnosis of MMN has decreased ( p Ͻ 0.0001) since the first descriptions 1,2 : from 1988 to 1995, median time to diagnosis was 5 years (range 1-15); from 1996 to 2000, 3 years (range 1-10); and from 2001 to 2006, 2 years (range 1-5).
Weakness. The median MRC sumscore was 166 (range 108 -179), with a pattern of predominant distal weakness, more pronounced in arms than legs. Table 2 shows the distribution and severity of muscle weakness. Finger flexors were relatively spared compared to other distal muscle groups in arms. Weakness of the upper leg was found in patients with disease duration of 20 years or longer.
Tendon reflexes. Seventy-three patients (83%) had 1 or more absent reflexes. In 7 patients (8%) all reflexes were normal. In 8 patients (9%) some or all reflexes were brisk (all reflexes 3 times; biceps and triceps reflexes 3 times; knee reflex 2 times); 7 of these 8 patients (8% of total) had weakness in the same segment where the tendon reflex was brisk. Brisk reflexes were easily elicitable reflexes, but without spread or clonus. Sensory function. Abnormal vibration sense in distal leg was found in 19 patients (22%); grade 1 (disturbed at the interphalangeal joint of the hallux) in 16 patients and grade 2 (disturbed at the medial malleolus) in 3 patients. The median disease duration was longer (median 18 years, range 5-43, p Ͻ 0.02) compared to patients without sensory symptoms.
Laboratory studies. Sera from 38 patients (43%) contained IgM anti-GM1 antibodies with titers 1:400 or higher (table 1) .
Nerve conduction studies. Seventy-one patients (81%) had at least 1 definite CB, and 16 patients (18%) had no definite but at least 1 probable CB. Six patients (7%) had only 1 definite CB (median, ulnar, radial, or musculocutaneous nerve), another 6 patients (7%) had only 1 probable CB (ulnar or median nerve). One patient (1%) had MCV and DML val- ues compatible with demyelination but no CB. This patient had elevated IgM anti-GM1 antibody titers and abnormal brachial plexus MRI, and fulfilled the criteria of possible MMN.
CB was most often detected in the ulnar (80%) and median nerves (77%) (table 3). In 5 patients (6%), CB was exclusively detected in the proximal (Erb-axilla) segment (3 times ulnar, 2 times radial nerves), and in 1 patient (1%) exclusively in the musculocutaneous nerve.
A decreased distal CMAP was most frequently found in the peroneal (66%) or median (60%) nerves followed by the tibial (47%), ulnar (37%), radial (21%), and musculocutaneous (10%) nerves. The number of nerves with a decreased distal CMAP in individual patients ranged from 0 to 10.
Functional impairment and fatigue. Median ODSS of arms and legs combined was 4 (range 0 -9). Sixteen patients (18%) reported minimal or no disability of the arms (ODSS 0 and 1). Fifty-four patients (61%) had moderate impairment of the arms (ODSS 2), whereas 18 patients (21%) reported severe disability (ODSS 3). Twenty-five patients (28%) had normal function of the legs (ODSS 0). Walking was mildly affected in 15 patients (17%) (ODSS 1). Forty-two patients (48%) walked independently but had abnormal gait (ODSS 2) and 6 patients (7%) needed unilateral support or a wheelchair (ODSS 3 to 6).
The mean response to the fatigue severity scale was 4.7 (range 2.7-7.0). Severe fatigue (FSS Ͼ5) was present in 45 patients (51%).
Treatment. Eighty-four patients (95%) had received a first IVIg course at a cumulative dose of 2 g/kg. Four patients had never received IVIg, because they experienced no problems in their daily life or had limited weakness. Seventy-nine of 84 patients (94%) responded to therapy, defined as an increase of Ն1 MRC grade in at least 2 muscle groups without a decrease in other muscle groups (95% CI, 86.8%- 97.4%). Five patients (6%) did not respond to IVIg. Lack of response was associated with more axon loss ( p Ͻ 0.01), and a longer disease duration before the first IVIg treatment ( p ϭ 0.03). Sixty-seven patients (76%) received IVIg maintenance treatment at time of this study. Median duration of maintenance treatment was 6 years (range 0 -17) and median dose, converted to grams per week, gradually increased over the years from 12 to 17 g/week ( p Ͻ 0.01). Seventeen patients (19%) did not use maintenance treatment for the following reasons: no beneficial effect (5 patients), stable disease course without treatment (8 patients), a concomitant disease (bipolar disorder and Waldenström macroglobulinemia), or adverse effects (severe erythema and thromboembolic complication).
Thirty-five (40%) patients had unsuccessfully used other immune-modulating therapy; interferon-␤ (20%), 29 mycophenolate mofetil (15%), 30 cyclophosphamide (3%), or prednisone (2%).
Correlates of outcome.
Univariate analysis suggested that more severe disability was associated with more axon loss, years untreated, symptom onset in a leg, and presence of IgM anti-GM1 antibodies; multivariate analysis identified only axon loss ( p Ͻ 0.0001) as an independent determinant of more severe disability (table 4). More severe weakness was associated with axon loss (univariate p Ͻ 0.0001; multivariate p Ͻ 0.001) and years untreated (univariate p Ͻ 0.01; multivariate p ϭ 0.03). DISCUSSION We performed a nationwide study on MMN, and identified 97 patients in the Netherlands, which corresponds to a prevalence of at least 0.6 per 100,000 inhabitants.
Our study not only confirmed that MMN is more prevalent in men than women 12, 13, 16 but also showed that symptom onset was at a younger age in males. Clinical presentation and patterns of weakness were fairly homogeneous, with onset in distal muscle groups of an arm or leg in the great majority of patients. Ulnar, median, radial, and tibial nerves were most commonly affected, with striking differences in weakness of muscles innervated by a common terminal nerve. For example, marked weakness of the abductor pollicis brevis, but relatively preserved function of the flexor muscles of the first 3 fingers (both innervated by the median nerve), and weakness of intrinsic hand muscles without weakness of the flexor muscles of fingers 4 and 5 (ulnar nerve). These findings suggest that pathogenic mechanisms are length-dependent but also patchy. 15, 16 Our results suggest that there are few reliable clinical hallmarks which suggest the diagnosis of MMN in a patient with asymmetric limb weakness. Brisk, but not pathologic, reflexes may occur even in weakened segments. Hence the finding of brisk reflexes but without spread or clonus may not always differentiate MMN from MND. Significant sensory disturbances from onset exclude MMN, and rather suggest Lewis-Sumner syndrome, 31 but recently published studies showed reduced sensory nerve action potentials years after MMN onset. 32, 33 We found minor vibration sense disturbances at neurologic examination in 22%. Sensory nerve conduction studies to confirm these clinical findings were not performed for this study. The median disease duration in the subgroup with sensory deficits in this study (18 years) and other studies was relatively long. [11] [12] [13] Nerve conduction studies are crucial to distinguish MMN from MND and other mimics. All participating patients fulfilled the criteria for MMN that were published by our own group. 18 In contrast to other criteria, this allowed inclusion of patients with possible MMN (conduction slowing compatible with demyelination in addition to elevated IgM anti-GM1 antibody titers or abnormal brachial plexus MRI). The use of other sets of diagnostic criteria would have resulted in the exclusion of some patients. Using the criteria proposed by the American Association of Electrodiagnostic Medicine, we would have excluded 13 patients (12 with only 1 CB and 1 patient without CB). 24 However, the findings that all 13 patients responded to IVIg, and 7 had IgM anti-GM1 antibodies, further support the diagnosis of MMN. The use of the electrophysiologic criteria of the European Federation of Neurological Societies/ Peripheral Nerve Society Guideline 34 would have resulted in exclusion of the only patient without CB, but with nerve conduction slowing, IgM anti-GM1 antibodies, and abnormal brachial plexus MRI. This patient responded to IVIg. This case and the use of an extensive nerve conduction protocol illustrate that CB can occasionally only be detected in proximal nerve segments or in nerves that are not routinely investigated, and that CB may also be absent in patients with a clinical phenotype of MMN. 35, 36 These rare patients should not be denied a trial with IVIg. MMN is considered as a benign disease, but functional impairment can be serious. One-fifth of our patients reported severe disability of the arms, and more than half of patients with MMN reported severe fatigue. Fatigue has a comparable prevalence among patients with other immune-mediated disorders of the peripheral nervous system. 37 Future studies are needed to study the origin, and possibly treatment, of fatigue in MMN. A relation with IVIg treatment cannot be excluded.
To analyze determinants of outcome, we used multivariate analysis, which showed that axon loss and years without treatment were associated with more severe weakness and disability. A decreased distal CMAP was used as criterion for axon loss in our study. 25, 26 Theoretically, a decreased distal CMAP may also reflect distal CB, or marked slowing distal to the most distal stimulation site. 38 However, stimulation of the median nerve distal to the wrist in 20 patients with MMN with a decreased thenar CMAP did not reveal CB (unpublished observation) and marked distal slowing was found only in 3% of nerves. 25 Needle EMG was not routinely performed for this study, but we previously published results of 20 patients with MMN in whom needle EMG was performed of each muscle from which a CMAP was recorded 39 showing a relatively good correlation: from 26 nerves with a low distal CMAP, 23 of the respective innervated muscles showed neurogenic changes on needle EMG (88%). In the same study we showed that axon loss, but not CB or demyelinative slowing, was an independent determinant of weakness in corresponding muscles. This was confirmed in the present study in which we were able to analyze more determinants due to the larger number of patients. The lack of correlation between CB or demyelinative slowing and severity of weakness may be explained by the finding that a substantial number (approximately one-third) of electrophysiologic abnormalities are found in nerves innervating nonweakened muscles. 25 In patients who received maintenance IVIg treatment, the median dose gradually increased over the years, indicating less response over time. This is consistent with a previous study showing that IVIg has a beneficial long-term effect on muscle strength and disability but could not prevent a slight decrease in muscle strength and increase of axon loss. 23 Our present finding that years untreated and not duration of IVIg treatment was a determinant for more severe weakness and disability indicates that progression of weakness and axon loss were more pronounced in the years without than in the years with IVIg treatment. Other studies have also shown that axon loss is more extensive in patients with long disease duration without treatment, 7, 39 and that IVIg treatment may prevent axon loss. 40 Results of this study indicate that an early start of IVIg, followed by maintenance treatment, is at present the only intervention that may prevent axonal degeneration and a more severe outcome. Elucidation of the pathogenesis of axon loss in MMN would facilitate the development of new treatment strategies. 
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